The Business Behind...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$1.43 -0.02 | -1.38%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 7.44M | 2.35M | 9.26M | 2.31M |
| Receivables | 3.33K | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 205.65K | 234.38K | 322.13K | 0.00 |
| Total Current Assets | 7.65M | 3.02M | 9.83M | 2.45M |
| Property, Plant & Equipment, Gross | 654.04K | 614.82K | 418.41K | 342.09K |
| Accumulated Depreciation & Depletion | 423.64K | 322.63K | 218.32K | 145.33K |
| Property, Plant & Equipment, Net | 230.40K | 292.19K | 200.08K | 196.76K |
| Intangibles | 807.36K | 701.85K | 500.15K | 301.56K |
| Other Non-Current Assets | 38.42K | 75.39K | 60.88K | 55.72K |
| Total Non-Current Assets | 1.10M | 1.07M | 761.11K | 554.03K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 8.75M | 4.09M | 10.59M | 3.01M |
| Accounts Payable | 1.20M | 1.84M | 1.03M | 791.61K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 90.78K | 0.00 | 1.25M | 0.00 |
| Total Current Liabilities | 1.76M | 2.43M | 2.74M | 1.56M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 21.14K | 0.00 | 0.00 | 6.46M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 21.14K | 0.00 | 0.00 | 6.46M |
| Total Liabilities | 1.78M | 2.43M | 2.74M | 8.02M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 6.97M | 1.66M | 7.85M | -5.02M |
| Common Par | 681.89K | 486.82K | 468.98K | 357.44K |
| Additional Paid In Capital | 114.88M | 99.65M | 93.34M | 62.19M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -108.59M | -98.47M | -85.95M | -67.57M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 6.97M | 1.66M | 7.85M | -5.02M |
| Total Equity | 6.97M | 1.66M | 7.85M | -5.02M |
| Total Liabilities & Stock Equity | 8.75M | 4.09M | 10.59M | 3.01M |
| Total Common Shares Outstanding | 68.19M | 48.68M | 46.90M | 35.74M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 58.15M | 48.34M | 43.47M | 34.28M |
| Diluted Weighted Shares Outstanding | 58.15M | 48.34M | 43.47M | 34.28M |
| Number of Employees | 16 | 14 | 14 | 8 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- Userjustin
- ContributorBreakout Stocks Of The Week...
Latest CUR Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 05.09.13 | 01:05 pm
- 4 Biotech Stocks Under $10 Moving Higher 11.27.12 | 02:11 pm
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- Stocks Close Week Higher on QE3 Confidence 09.14.12 | 05:09 pm
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 5 Stocks Poised for Big Breakouts 08.31.12 | 01:08 pm
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
Press Releases for CUR
- Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention - PR Newswire 04.18.13 | 09:04 am
- Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis - PR Newswire 04.17.13 | 08:04 am
- Nominations Pursuant To Advance Notice Policy - PR Newswire 04.15.13 | 07:04 am
- DiagnoCure's Adoption Of An Advance Notice Policy - PR Newswire 04.09.13 | 08:04 am
- Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis - PR Newswire 04.05.13 | 09:04 am
- DiagnoCure Joins The OTCQX Marketplace And S&P Corporation Records Listing - PR Newswire 04.02.13 | 07:04 am
- DiagnoCure Begins Trading On OTCQX® - PR Newswire 04.02.13 | 07:04 am
- Neuralstem Secures $8 Million In Debt Financing From Hercules - PR Newswire 03.25.13 | 09:03 am
- Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers" - PR Newswire 03.14.13 | 09:03 am
- Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center - PR Newswire 02.20.13 | 09:02 am
Partner Headlines for CUR
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 4 Biotechs That Just Got Mauled By Bears - Seeking Alpha 10.10.12 | 09:10 am
- Morning Market Movers - Benzinga 10.04.12 | 09:10 am
- Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial - Benzinga 10.04.12 | 09:10 am
- Neuralstem Grants First Licenses for CNS Therapy Surgical Devices - Benzinga 09.06.12 | 09:09 am
- ALS Patient's Survival is "One of the Most Powerful Stories" Ever Reported - Benzinga 08.27.12 | 01:08 pm
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
